OSTX

OS Therapies Incorporated

OSTX

Market cap $70.9M

Overview Fund Activity

2.24 USD

+0.04

1.82%

At close Updated Sep 16, 12:17 PM EDT

1 day

1.82%

5 days

3.7%

1 month

2.75%

3 months

17.89%

6 months

37.42%

Year to date

-46.41%

1 year

-36.72%

5 years

-10.76%

10 years

-10.76%

About: OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.

Employees: 5

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

117% more funds holding

Funds holding: 6 [Q1] → 13 (+7) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

89% more capital invested

Capital invested by funds: $599K [Q1] → $1.13M (+$535K) [Q2]

0.36% more ownership

Funds ownership: 1.79% [Q1] → 2.15% (+0.36%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$20

793% upside

Avg. target

$20

793% upside

High target

$20

793% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital

Jason Kolbert

$20

Buy

Maintained

12 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about OSTX published over the past 30 days

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Clinical data from Phase 1b prostate cancer trial to be released in Q4/25 Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma to be released on October 10, 2025 New York, New York--(Newsfile Corp. - September 12, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that the last patient enrolled in its OST-504 (previously ADXS-504) Phase 1b clinical trial in subjects with biochemically recurrent prostate cancer previously treated with radical prostatectomy (RP) or radiation therapy (external beam or brachytherapy) who are not currently receiving androgen ablation therapy has completed their last patient visit (NCT05077098). A total of 7 patients enrolled in the study.

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Dallas, Texas--(Newsfile Corp. - September 8, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners initiates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies advanced meaningful clinical, regulatory, and financial milestones in 2Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma.

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences: Cantor Global Healthcare Conference 2025 being held September 3-5, 2025 in New York City. Management will be available for meetings with institutional investors and brokers H.C.

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Company on track to begin submission of a rolling Biologics Licensing Application (BLA) request for OST-HER2 to U.S. Food & Drug Administration in September 2025 New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today provided stakeholders with a detailed update regarding the Company's OST-HER2 recurrent, fully resected, pulmonary metastatic osteosarcoma program (the "Metastatic Osteosarcoma Program") following a highly productive End of Phase 2 Meeting with the US Food & Drug Administration ("FDA"). The Company remains on track to begin rolling submission of a Biologics Licensing Application ("BLA") request to FDA for the Metastatic Osteosarcoma Program in September 2025.

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

All remaining holders of outstanding warrants with $1.12 per share exercise price have participated, raising $3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparations New warrants issued have an exercise price of $3.00 per share with a forced exercise provision when the stock trades above $9.00 New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has completed a warrant inducement and exchange offer with the holders of all remaining outstanding warrants with an exercise price $1.12 per share issued in connection with a private placement with an initial closing date of December 31, 2024 (the "Warrant Exchange"). The Company completed the Warrant Exchange on substantially similar terms to the previously announced warrant exercise inducement and exchange offer on July 14, 2025.

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

New York, New York--(Newsfile Corp. - August 27, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed update regarding the Company's highly constructive August 27, 2025 End of Phase 2 Meeting with the US Food & Drug Administration ("FDA") discussing the regulatory path forward towards approval for OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma on Tuesday, September 2, 2025. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

OS Therapies Terminates Equity Line of Credit

New York, New York--(Newsfile Corp. - August 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it terminated its Equity Purchase Agreement (the "ELOC") with Square Gate Capital Master Fund, LLC — Series 3, effective August 26, 2025. "The recent success of our warrant exercise inducement and exchange offering provided the Company with $4.2 million in gross proceeds to fund operations into mid-year 2026, through the priority review voucher sunset date of September 30, 2026," said Paul Romness, MPH, Chairman & CEO of OS Therapies.

OS Therapies Terminates Equity Line of Credit

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

U.S. FDA ("FDA") confirms OST-HER2 meets biological definition of Regenerative Medicine Advanced Therapy (RMAT) FDA issues OST-HER2 BLA number in preparation for Accelerated Approval submission following End of Phase 2 Meeting FDA End of Phase 2 Meeting scheduled for August 27, 2025 to review Phase 2b clinical trial in the prevention or delay of recurrent, pulmonary metastatic osteosarcoma Statistically significant 12-month Event Free Survival and interim 2-year Overall Survival and strong safety data in Phase 2b trial drives global accelerated/conditional approval pathways Commercial partnership with Eversana positions OST-HER2 for possible U.S. launch in first half of 2026 $4.2 million capital raise, closed July 11, 2025 via warrant exercise inducement and exchange offering, extends cash runway into mid-2026 NYSE American-listed OSTX included in the Russell Microcap, Russell Microcap Value and Russell Microcap Growth indexes New York, New York--(Newsfile Corp. - August 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported second quarter 2025 financial results ended June 30, 2025 and provided a business update. "The Company gained significant momentum in the second quarter as we began to make meaningful clinical and regulatory progress on our path towards bringing the first new treatment for osteosarcoma to market in the United States in the last 40 years," said Paul Romness, MPH, Chairman & CEO of OS Therapies.

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046) FDA issues Biologics Licensing Application (BLA) number for OST-HER2 in preparation for anticipated BLA filing for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma following August 27, 2025 End of Phase 2 Meeting Company responds to FDA correspondences seeking to align approval metrics for Regenerative Medicine Advanced Therapy (RMAT) designation, Breakthrough Therapy designation (BTD) and Biologics Licensing Application via Accelerated Approval Program Company's NYSE American listing included in the Russell Microcap, Russell Microcap Value and Russell Microcap Growth indexes New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced statistically significant positive updated interim 2-year overall survival data from the Company's Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma. 66.6% (18 out of 27) of OST-HER2 treated patients achieved 2-year overall survival compared with 40% of historical control1 (p = 0.0046).

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

See News Rankings

Charts implemented using Lightweight Charts™